Literature DB >> 27335021

[Hemato-oncological imaging : Importance of hybrid procedures].

M E Mayerhoefer1, A Haug2.   

Abstract

CLINICAL/METHODICAL ISSUE: Biomedical imaging procedures play a major role in hemato-oncological diseases with respect to pre-therapeutic staging and assessment of treatment response. STANDARD RADIOLOGICAL
METHODS: Originally, the therapeutic management was the domain of computed tomography (CT) and whole-body magnetic resonance imaging (MRI). METHODICAL INNOVATIONS: Over the last decade these purely morphological techniques have gradually been replaced by hybrid imaging techniques, such as positron emission tomography-CT (PET/CT) and PET/MRI, which also provide metabolic and functional information. PERFORMANCE: For lymphomas, the PET tracer 18F-fluorodeoxyglucose (18 F-FDG) is meanwhile so well-established that its use is a cornerstone of the Lugano classification; however, for multiple myeloma the search for an optimal PET tracer that can also detect early disease stages is still ongoing. Functional MRI techniques, such as diffusion-weighted imaging (DWI), perfusion-weighted imaging and dynamic contrast-enhanced imaging have shown promising results for both lymphomas and multiple myelomas. ACHIEVEMENTS: The PET/MRI technique can combine the different types of information due to its truly multiparametric approach. PRACTICAL RECOMMENDATIONS: In the future PET/MRI could possibly become the hybrid imaging technique of choice for hemato-oncological diseases.

Entities:  

Keywords:  18F Fluorodeoxyglucose; Multiparametric approach; Positron emission tomography; Staging; Therapy response

Mesh:

Substances:

Year:  2016        PMID: 27335021     DOI: 10.1007/s00117-016-0126-6

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  35 in total

1.  (11)C-acetate as a new biomarker for PET/CT in patients with multiple myeloma: initial staging and postinduction response assessment.

Authors:  Chieh Lin; Chi-Lai Ho; Shu-Hang Ng; Po-Nan Wang; Yenlin Huang; Yu-Chun Lin; Tzung-Chih Tang; Shu-Fan Tsai; Alain Rahmouni; Tzu-Chen Yen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-10-16       Impact factor: 9.236

Review 2.  Current and future imaging modalities for multiple myeloma and its precursor states.

Authors:  Esther Tan; Brendan M Weiss; Esther Mena; Neha Korde; Peter L Choyke; Ola Landgren
Journal:  Leuk Lymphoma       Date:  2011-06-08

3.  Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.

Authors:  Bruce D Cheson; Richard I Fisher; Sally F Barrington; Franco Cavalli; Lawrence H Schwartz; Emanuele Zucca; T Andrew Lister
Journal:  J Clin Oncol       Date:  2014-09-20       Impact factor: 44.544

Review 4.  The 2016 revision of the World Health Organization classification of lymphoid neoplasms.

Authors:  Steven H Swerdlow; Elias Campo; Stefano A Pileri; Nancy Lee Harris; Harald Stein; Reiner Siebert; Ranjana Advani; Michele Ghielmini; Gilles A Salles; Andrew D Zelenetz; Elaine S Jaffe
Journal:  Blood       Date:  2016-03-15       Impact factor: 22.113

5.  11C-acetate PET/CT for metabolic characterization of multiple myeloma: a comparative study with 18F-FDG PET/CT.

Authors:  Chi-lai Ho; Sirong Chen; Yim Lung Leung; Thomas Cheng; Ka-nin Wong; Shing Kee Cheung; Raymond Liang; Chor Sang Chim
Journal:  J Nucl Med       Date:  2014-03-27       Impact factor: 10.057

6.  Incidental Detection of a Hodgkin Lymphoma on 18F-Choline PET/CT and Comparison With 18F-FDG in a Patient With Prostate Cancer.

Authors:  Aurore Goineau; Mathilde Colombié; Caroline Rousseau; Sophie Sadot-Lebouvier; Stéphane Supiot
Journal:  Clin Nucl Med       Date:  2015-08       Impact factor: 7.794

7.  F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma.

Authors:  Twyla B Bartel; Jeff Haessler; Tracy L Y Brown; John D Shaughnessy; Frits van Rhee; Elias Anaissie; Terri Alpe; Edgardo Angtuaco; Ronald Walker; Joshua Epstein; John Crowley; Bart Barlogie
Journal:  Blood       Date:  2009-05-14       Impact factor: 22.113

8.  Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group.

Authors: 
Journal:  Br J Haematol       Date:  2003-06       Impact factor: 6.998

9.  Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging.

Authors:  Hans Jürgen Wester; Ulrich Keller; Margret Schottelius; Ambros Beer; Kathrin Philipp-Abbrederis; Frauke Hoffmann; Jakub Šimeček; Carlos Gerngross; Michael Lassmann; Ken Herrmann; Natalia Pellegata; Martina Rudelius; Horst Kessler; Markus Schwaiger
Journal:  Theranostics       Date:  2015-03-01       Impact factor: 11.556

10.  11C-Methionine-PET: a novel and sensitive tool for monitoring of early response to treatment in multiple myeloma.

Authors:  Katharina Lückerath; Constantin Lapa; Christa Albert; Ken Herrmann; Gerhard Jörg; Samuel Samnick; Herrmann Einsele; Stefan Knop; Andreas K Buck
Journal:  Oncotarget       Date:  2015-04-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.